Skip to main content
. 2022 Apr 21;8(3):e83. doi: 10.1192/bjo.2022.44

Fig. 1.

Fig. 1

Comparison of clinical behaviour scores for the use of clinical guidelines at baseline and after the ‘Guideline for Pharmacological Therapy of Schizophrenia’ and ‘Treatment Guideline II: Major Depressive Disorder’ programmes. The x- and y-axes indicate the score for each question at baseline and the score for each question after programme participation, respectively. Details of each score are shown in Tables 1–3. Blue circles indicate clinical behaviour scores that increased significantly 1 year after attending the ‘Guideline for Pharmacological Therapy of Schizophrenia’ programme, compared with before the course (S1–S14). Blue triangles indicate clinical behaviour scores that increased significantly 2 years after attending the ‘Guideline for Pharmacological Therapy of Schizophrenia’ programme, compared with before the course (S1–S7, S9–S14). Green circles indicate clinical behaviour scores that increased significantly 1 year after attending the ‘Treatment Guideline II: Major Depressive Disorder’ programme, compared with before the course (D1–D14). Green triangles indicate clinical behaviour scores that increased significantly 2 years after attending the ‘Treatment Guideline II: Major Depressive Disorder’ programme, compared with before the course (D1–D14). Red circles indicate clinical behaviour scores that increased significantly 1 year after attending the ‘Guideline for Pharmacological Therapy of Schizophrenia’ and ‘Treatment Guideline II: Major Depressive Disorder’ programmes, compared with before the course (G1–G6). Red triangles indicate clinical behaviour scores that increased significantly 2 years after attending the ‘Guideline for Pharmacological Therapy of Schizophrenia’ and ‘Treatment Guideline II: Major Depressive Disorder’ programmes, compared with before the course (G1–G6). Solid blue triangles indicate clinical behaviour scores that were not significantly elevated 2 years after attending the ‘Guidelines for the Pharmacotherapy of Schizophrenia’ programme compared with before the programme (S8).